BIIB Share Price

Open 284.28 Change Price %
High 286.35 1 Day -1.64 -0.58
Low 281.08 1 Week -4.00 -1.39
Close 283.11 1 Month -3.29 -1.15
Volume 1962701 1 Year 9.78 3.58
52 Week High 333.65
52 Week Low 223.02
BIIB Important Levels
Resistance 2 288.00
Resistance 1 285.98
Pivot 283.51
Support 1 280.24
Support 2 278.22
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
AAPL 119.97 0.78%
More..
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
AMCF 0.06 50.00%
LOCM 0.09 50.00%
REXX 0.74 42.31%
CWEI 145.25 39.69%
CLSN 0.51 30.77%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 4.95 22.83%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Biogen Idec Inc. (NASDAQ: BIIB)

BIIB Technical Analysis 2
As on 17th Jan 2017 BIIB Share Price closed @ 283.11 and we RECOMMEND Buy for LONG-TERM with Stoploss of 281.95 & Strong Sell for SHORT-TERM with Stoploss of 294.89 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIIB Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
BIIB Other Details
Segment EQ
Market Capital 33194547200.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biogenidec.com
BIIB Address
BIIB
225 Binney Street
Cambridge, MA 02142
United States
Phone: 781-464-2000
Interactive Technical Analysis Chart Biogen Idec Inc. ( BIIB NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biogen Idec Inc.
BIIB Business Profile
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.